| Name | Title | Contact Details |
|---|---|---|
Angad Singh |
Chief Technology Officer | Profile |
Annexon is a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders of the body, brain and eye. The company`s pipeline is based on its platform technology addressing a broad spectrum of well-researched classical complement-mediated autoimmune and neurodegenerative diseases triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon is advancing a portfolio of innovative product candidates designed to block the activity of C1q and the entire classical complement pathway: ANX005 (intravenous administration), ANX007 (intravitreal administration) and ANX009 (subcutaneous administration). Annexon is deploying a disciplined, biomarker-driven strategy designed to improve the probability of technical success of its portfolio.
Celsis Inc is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Scientist.com is the world's largest online research marketplace.
Hazel Technologies develops products that extend the shelf life of produce. Our customers include some of the largest produce growers in the world.
Transave is a Monmouth Junction, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.